NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

BTAI

BioXcel Therapeutics Inc

Apr 25 • 04:00PM ET

1.87

Dollar change +0.02
Percentage change 1.08	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN AMGN BIIB INCY NBIX SAGE ACAD ONC EXEL

| Held by: VXF IWC BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-25.91	Insider Own	16.92%	Shs Outstand	5.49M	Perf Week	7.47%
Market Cap	10.26M	Forward P/E	-	EPS next Y	-23.76	Insider Trans	-0.51%	Shs Float	4.56M	Perf Month	-14.22%
Income	-59.60M	PEG	-	EPS next Q	-2.72	Inst Own	9.76%	Short Float	1.63%	Perf Quarter	-65.62%
Sales	2.27M	P/S	4.52	EPS this Y	30.09%	Inst Trans	229.36%	Short Ratio	0.02	Perf Half Y	-79.94%
Book/sh	-30.01	P/B	-	EPS next Y	-44.57%	ROA	-106.39%	Short Interest	0.07M	Perf Year	-96.06%
Cash/sh	5.44	P/C	0.34	EPS next 5Y	-	ROE	-	52W Range	1.29 - 43.52	Perf YTD	-68.74%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.20%	ROI	-629.21%	52W High	-95.70%	Beta	0.08
Dividend TTM	-	Quick Ratio	1.65	Sales past 5Y	66.44%	Gross Margin	-8.25%	52W Low	44.96%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	1.68	EPS Y/Y TTM	73.71%	Oper. Margin	-2801.15%	RSI (14)	46.66	Volatility	7.57% 12.42%
Employees	37	Debt/Eq	-	Sales Y/Y TTM	64.20%	Profit Margin	-2630.14%	Recom	2.50	Target Price	24.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	70.45%	Payout	-	Rel Volume	0.01	Prev Close	1.85
Sales Surprise	18.18%	EPS Surprise	40.93%	Sales Q/Q	-2.66%	Earnings	Mar 27 BMO	Avg Volume	4.55M	Price	1.87
SMA20	4.24%	SMA50	-12.79%	SMA200	-75.80%	Trades		Volume	35,748	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-21-24	Downgrade	UBS	Buy → Neutral	$9 → $4
Aug-15-23	Downgrade	Mizuho	Buy → Neutral	$40 → $4
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold	$20 → $22
Dec-01-22	Upgrade	Goldman	Sell → Neutral	$16
Jul-07-22	Initiated	Mizuho	Buy	$19
Apr-06-22	Reiterated	BofA Securities	Buy	$80
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$55 → $24
Apr-09-21	Initiated	Berenberg	Buy	$75
Feb-01-21	Initiated	UBS	Buy	$99
Oct-30-20	Initiated	Goldman	Buy	$60
Sep-02-20	Initiated	Jefferies	Buy	$82
Aug-17-20	Reiterated	H.C. Wainwright	Buy	$200 → $175
Jul-08-20	Reiterated	H.C. Wainwright	Buy	$95 → $120
Jun-04-20	Initiated	Guggenheim	Buy	$101
Apr-01-20	Initiated	BofA/Merrill	Buy	$45
Feb-26-20	Reiterated	H.C. Wainwright	Buy	$30 → $95
Jan-08-20	Reiterated	H.C. Wainwright	Buy	$25 → $30
Nov-12-19	Initiated	SunTrust	Buy	$24

Show Previous Ratings

Apr-16-25 08:58AM	WHO and WEF Are Pushing AI in Global Healthcare -- What It Means for the Market (PR Newswire)
Mar-27-25 08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.96%
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 (GlobeNewswire)
Mar-20-25 06:50PM	TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Mar-19-25 05:10PM	ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +7.73%
02:13PM	Loading…
02:13PM	Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight (Zacks)
Mar-11-25 07:00AM	BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) -16.84%
Mar-09-25 06:05PM	Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week (Insider Monkey)
Mar-07-25 07:00AM	BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire) +22.99%
Mar-04-25 04:15PM	BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering (GlobeNewswire) -28.00%
10:00AM	BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Mar-03-25 03:33PM	BioXcel Therapeutics Announces $14 Million Registered Direct Offering (GlobeNewswire) +73.61%
07:00AM	BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia (GlobeNewswire)
Feb-28-25 07:00AM	BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) +24.86%
Feb-06-25 07:00AM	BioXcel Therapeutics Announces Reverse Stock Split (GlobeNewswire) -37.57%
07:00AM	Loading…
Feb-05-25 07:00AM	BioXcel Therapeutics Provides Clinical and Business Update (GlobeNewswire)
Dec-23-24 12:00PM	BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Nov-22-24 08:16AM	BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -10.80%
Nov-21-24 04:47PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Nov-15-24 02:07AM	BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... (GuruFocus.com) +9.20%
Nov-14-24 11:13PM	Q3 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
08:20AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-13-24 07:31AM	What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings (GuruFocus.com) -6.92%
Nov-12-24 07:00AM	BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia (GlobeNewswire) -7.61%
Nov-08-24 07:00AM	BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 (GlobeNewswire)
Nov-05-24 10:00AM	Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-29-24 07:00AM	BioXcel Therapeutics to Present at ThinkEquity Conference (GlobeNewswire) +6.57%
Oct-15-24 07:00AM	BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder (GlobeNewswire) +6.06%
Sep-19-24 07:00AM	BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation (GlobeNewswire)
01:22AM	Loading…
Sep-12-24 01:22AM	FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares (GuruFocus.com)
Sep-05-24 07:00AM	BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
Aug-30-24 09:55AM	BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-07-24 07:00AM	BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire) -5.06%
01:31AM	Q2 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 08:10AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 07:00AM	BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire) -6.84%
Jul-16-24 07:00AM	BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +9.84%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire)
May-28-24 07:00AM	BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 07:00AM	BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-10-24 11:58AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.33%
May-09-24 11:31PM	Q1 2024 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.73%
11:58AM	BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	BioXcel Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-24-24 10:30AM	BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting (GlobeNewswire) -8.75%
Apr-22-24 07:00AM	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential (GlobeNewswire)
Apr-10-24 07:00AM	BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia (GlobeNewswire)
Mar-25-24 07:00AM	BioXcel Therapeutics Announces $25 Million Registered Direct Offering (GlobeNewswire)
Mar-15-24 07:00AM	BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine (GlobeNewswire) -6.62%
Mar-13-24 08:57AM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-12-24 09:48PM	Q4 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-01-24 07:00AM	BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey)
Feb-14-24 08:30AM	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies (GlobeNewswire) +26.02%
Feb-13-24 09:00AM	BioXcel Therapeutics Announces Termination of Proposed Public Offering (GlobeNewswire) +26.15%
Feb-12-24 07:14AM	BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) (GlobeNewswire) -7.58%
Feb-09-24 09:05AM	Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today? (InvestorPlace) -43.73%
Feb-08-24 04:01PM	BioXcel Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Feb-06-24 07:00AM	BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA (GlobeNewswire) +8.89%
Feb-05-24 07:00AM	BioXcel Therapeutics Announces USPTO's Allowance of Patent Application for Method of Treating Agitation in Alzheimer's Disease Using Oromucosal Formulations of Dexmedetomidine (GlobeNewswire) +21.24%
Dec-12-23 07:00AM	BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today (GlobeNewswire)
Dec-11-23 07:00AM	BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs (GlobeNewswire)
Dec-01-23 07:29PM	Moore Kuehn, PLLC Encourages BioXcel Therapeutics, Inc. Investors to Contact Law Firm (PR Newswire)
Nov-30-23 07:00AM	BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023 (GlobeNewswire)
Nov-24-23 06:40AM	7 Penny Stocks With Low Floats and High Short Interest (InvestorPlace)
Nov-15-23 02:23PM	BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:27AM	Q3 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:52AM	BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results and Strategic Updates (GuruFocus.com) -23.41%
07:00AM	BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-08-23 07:00AM	BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype (GlobeNewswire)
Nov-06-23 07:00AM	BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD) (GlobeNewswire)
Oct-31-23 07:00AM	BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Oct-30-23 07:00AM	BioXcel Therapeutics Receives Permanent J-Code for IGALMI (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services (GlobeNewswire) +31.68%
Oct-25-23 09:18AM	Why Is BioXcel Therapeutics (BTAI) Stock Up 42% Today? (InvestorPlace) +20.94%
07:00AM	BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site (GlobeNewswire)
Oct-17-23 10:26AM	BTAI: BXCL701 Shows Positive Overall Survival Results in Phase 2 Trial (Zacks)
Oct-10-23 09:45AM	Investors in BioXcel Therapeutics, Inc. (NASDAQ: BTAI) should contact the Shareholders Foundation in connection with a Lawsuit (GlobeNewswire) +21.53%
07:00AM	BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer (GlobeNewswire)
Oct-04-23 07:00AM	BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI (dexmedetomidine) Sublingual Film (GlobeNewswire) +13.25%
Sep-28-23 05:35PM	Why Shares of BioXcel Therapeutics Fell This Week (Motley Fool) -9.12%
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-17-23 10:30AM	BTAI: Strategic Reprioritization Underway... (Zacks) +5.04%
Aug-15-23 05:43PM	Why BioXcel Therapeutics Stock Flopped Again Today (Motley Fool)
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 11:04PM	Q2 2023 BioXcel Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -41.49%
12:44PM	3 Biotech Stocks to Sell in August Before They Crash and Burn (InvestorPlace)
12:01PM	Why BioXcel Therapeutics Stock Is Getting Crushed Today (Motley Fool)
07:24AM	BioXcel cuts over 50% jobs as it pivots focus to retail market for agitation drug (Reuters)
07:21AM	UPDATE 2-BioXcel to cut over 50% of jobs as it pivots focus to agitation drug (Reuters)
07:06AM	BioXcel announces job cuts (Reuters)
07:00AM	BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization (GlobeNewswire)
Jul-31-23 07:00AM	BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023 (GlobeNewswire)
Jul-07-23 08:16AM	Why BioXcel Therapeutics Stock Was Bouncing Back This Week (Motley Fool) -6.53%
Jul-05-23 10:20AM	BTAI: Positive Data for TRANQUILITY II Trial Overshadowed by Possible Trial Mismanagement (Zacks Small Cap Research) +42.26%

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Neill Vincent	See Remarks	Dec 16 '24	Sale	0.35	165	58	19,957	Dec 17 06:10 PM
Mehta Vimal	CEO and President	Dec 16 '24	Sale	0.36	3,117	1,131	59,605	Dec 17 06:08 PM
Steinhart Richard I	Chief Financial Officer	Dec 16 '24	Sale	0.36	577	207	20,932	Dec 17 06:06 PM
Rodriguez Javier	See Remarks	Dec 16 '24	Sale	0.36	430	153	24,423	Dec 17 06:04 PM
Yocca Frank	Chief Scientific Officer	Dec 16 '24	Sale	0.35	430	152	28,931	Dec 17 06:03 PM
O'Neill Vincent	Officer	Dec 16 '24	Proposed Sale	0.35	165	58		Dec 16 04:21 PM
Rodriguez Javier	Officer	Dec 16 '24	Proposed Sale	0.36	430	153		Dec 16 03:59 PM
Yocca Frank	Officer	Dec 16 '24	Proposed Sale	0.35	430	152		Dec 16 03:23 PM
Steinhart Richard I	Officer	Dec 16 '24	Proposed Sale	0.35	438	154		Dec 16 03:00 PM
Mehta Vimal	Officer	Dec 16 '24	Proposed Sale	0.35	983	340		Dec 16 02:10 PM
Wiley Matthew T.	Chief Commercial Officer	Oct 03 '24	Sale	0.55	6,272	3,450	19,011	Oct 03 09:55 PM
Rodriguez Javier	See Remarks	Oct 03 '24	Sale	0.55	6,863	3,775	23,770	Oct 03 09:55 PM
Yocca Frank	Chief Scientific Officer	Oct 03 '24	Sale	0.55	7,175	3,946	28,278	Oct 03 09:54 PM
Steinhart Richard I	Chief Financial Officer	Oct 03 '24	Sale	0.55	7,175	3,946	20,279	Oct 03 09:54 PM
O'Neill Vincent	See Remarks	Oct 03 '24	Sale	0.55	5,556	3,056	19,601	Oct 03 09:53 PM
Rodriguez Javier	Officer	Oct 03 '24	Proposed Sale	0.55	6,863	3,776		Oct 03 04:40 PM
Wiley Matthew T.	Officer	Oct 03 '24	Proposed Sale	0.55	6,272	3,450		Oct 03 04:33 PM
O'Neill Vincent	Officer	Oct 03 '24	Proposed Sale	0.55	5,556	3,056		Oct 03 04:25 PM
Yocca Frank	Officer	Oct 03 '24	Proposed Sale	0.55	7,175	3,946		Oct 03 04:17 PM
Steinhart Richard I	Officer	Oct 03 '24	Proposed Sale	0.55	7,175	3,947		Oct 03 04:02 PM
Yocca Frank	Chief Scientific Officer	Sep 16 '24	Sale	0.69	355	245	14,203	Sep 17 07:23 PM
Mehta Vimal	CEO and President	Sep 16 '24	Sale	0.69	1,982	1,367	51,666	Sep 17 07:21 PM
Steinhart Richard I	Chief Financial Officer	Sep 16 '24	Sale	0.69	356	246	6,204	Sep 17 07:21 PM
Rodriguez Javier	See Remarks	Sep 16 '24	Sale	0.69	345	238	9,133	Sep 17 07:20 PM
O'Neill Vincent	See Remarks	Sep 16 '24	Sale	0.69	138	95	3,907	Sep 17 07:19 PM
Wiley Matthew T.	Chief Commercial Officer	Sep 16 '24	Sale	0.69	215	149	4,033	Sep 17 07:18 PM
Yocca Frank	Officer	Sep 16 '24	Proposed Sale	0.69	355	245		Sep 16 05:42 PM
Wiley Matthew T.	Officer	Sep 16 '24	Proposed Sale	0.69	215	149		Sep 16 05:26 PM
Rodriguez Javier	Officer	Sep 16 '24	Proposed Sale	0.69	345	238		Sep 16 05:16 PM
O'Neill Vincent	Officer	Sep 16 '24	Proposed Sale	0.69	138	95		Sep 16 03:48 PM
Steinhart Richard I	Officer	Sep 16 '24	Proposed Sale	0.69	356	246		Sep 16 02:58 PM
Mehta Vimal	Officer	Sep 16 '24	Proposed Sale	0.69	832	574		Sep 16 01:23 PM
Yocca Frank	Chief Scientific Officer	Jun 17 '24	Sale	1.28	372	476	13,474	Jun 18 09:27 PM
Wiley Matthew T.	Chief Commercial Officer	Jun 17 '24	Sale	1.26	244	308	3,498	Jun 18 09:26 PM
Steinhart Richard I	Chief Financial Officer	Jun 17 '24	Sale	1.26	372	470	5,476	Jun 18 09:26 PM
Rodriguez Javier	See Remarks	Jun 17 '24	Sale	1.26	361	456	8,394	Jun 18 09:25 PM
O'Neill Vincent	See Remarks	Jun 17 '24	Sale	1.28	155	199	3,524	Jun 18 09:25 PM
Mehta Vimal	CEO and President	Jun 17 '24	Sale	1.28	2,134	2,739	47,539	Jun 18 09:24 PM
Mehta Vimal	CEO and President	Jun 04 '24	Sale	1.63	126,014	205,516	7,811,515	Jun 06 08:35 PM
Mehta Vimal	CEO and President	Jun 05 '24	Sale	1.58	126,014	199,619	7,685,501	Jun 06 08:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BTAI

BioXcel Therapeutics Inc

Upgrade your FINVIZ experience